Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisia pollen allergen extract is a form of allergen-specific immunotherapy (AIT) used to treat allergic rhinitis and/or conjunctivitis caused by sensitization to pollen from plants of the Artemisia genus (e.g., mugwort). [5, 16] The therapy works by administering controlled doses of the allergen extract to the patient, typically via sublingual or subcutaneous routes, to desensitize the immune system. [14, 24] This process aims to induce immunological tolerance, thereby reducing the severity of allergic symptoms upon natural exposure to the pollen. Clinical trials have demonstrated its efficacy and safety in both adult and pediatric populations. [2, 4, 7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artemisia pollen allergen extract.